Patients with persistent atrial fibrillation.
This medication is approved to treat paroxysmal atrial fibrillation (intermittent), persistent atrial fibrillation, or atrial flutter. It was approved by the F.D.A. in 2009 after the ATHENA clinical trial showed that it decreased deaths in patients with non-permanent atrial fibrillation and atrial flutter.
(Source: F.D.A. MedWatch Alert, August 2011.)
|Printer friendly Cite/link Email Feedback|
|Publication:||Nutrition Health Review|
|Date:||Jun 22, 2011|
|Previous Article:||American Academy of Pediatrics' circumcision policy.|
|Next Article:||Adverse drug events such as esophagitis.|